<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04698616</url>
  </required_header>
  <id_info>
    <org_study_id>SJ-823</org_study_id>
    <nct_id>NCT04698616</nct_id>
  </id_info>
  <brief_title>Lean Body Mass and Side Effects in Patients With Lymphoma</brief_title>
  <official_title>The Relation Between Lean Body Mass and Side Effects Induced by Chemotherapy in Patients With Lymphoma: A Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jens Rikardt Andersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose is to investigate the relationship between the dose of chemotherapeutic&#xD;
      agents per kilogram of lean body mass (LBM) and the development of side effects induced by&#xD;
      chemotherapy in patients with lymphoma. Secondarily, the maximum tolerable dose of&#xD;
      chemotherapeutics (MTD), patients' quality of life (QOL), nutritional status and physical&#xD;
      activity during the course of treatment are estimated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2020</start_date>
  <completion_date type="Anticipated">March 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lean Body Mass (LBM)</measure>
    <time_frame>8 weeks (two treatment cycles)</time_frame>
    <description>LBM measured by bioelectrical impedans corelated to the dosis of chemotherapeutics given</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal tolerable dose of chemotherapeutics (microg/ml/kg LBM),</measure>
    <time_frame>8 weeks (two treatment cycles)</time_frame>
    <description>Patients with side effects - correlation between dose of cytostatics/ kg LBM compared to patients without side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL) (score EORTC)</measure>
    <time_frame>8 weeks (two treatment cycles)</time_frame>
    <description>Correlation of score and difference in LBM (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nutritional status at inclusion (NRS2002 - scale)</measure>
    <time_frame>8 weeks (two treatment cycles)</time_frame>
    <description>Predictive value of scale for ocurrence of side-effects (binary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical activity (scale - questionaire)</measure>
    <time_frame>8 weeks (two treatmenr cycles)</time_frame>
    <description>Corelation between cytostatic dose/kg LBM and scale</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">141</enrollment>
  <condition>Malignant Lymphoma</condition>
  <arm_group>
    <arm_group_label>Malignant lymphoma patients</arm_group_label>
    <description>Identification of the patients who are/are not dose-reduced due to chemotherapy, and then look at the body composition in connection with this.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving myelosuppressive treatment for malignant lymphoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients receiving myelosuppressive treatment for malignant lymphoma assessed by the&#xD;
             investigator.&#xD;
&#xD;
          -  Legal of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ECOG Performance Status ≥2&#xD;
&#xD;
          -  People who cannot speak and understand Danish&#xD;
&#xD;
          -  Pregnant and breastfeeding&#xD;
&#xD;
          -  Dementia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens R Andersen, MD,MPA</last_name>
    <role>Study Chair</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Bjørn Poulsen, MD, PhD</last_name>
    <phone>+45 47324809</phone>
    <email>cbpo@regionsjaelland.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jens R Andersen, MD,MPA</last_name>
    <phone>+4523346654</phone>
    <email>jra@post3.tele.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <state>Frederiksberg</state>
        <zip>1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sjællands Universitetshospital, Hæmatologisk Afdeling H60</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Bjørn Poulsen, MD,PhD</last_name>
      <phone>+45 47324809</phone>
      <email>cbpo@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Anna-Lisa Malene Glavind Egeberg, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stine Kjørup Andersen, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Jens Rikardt Andersen</investigator_full_name>
    <investigator_title>Sponsor - Investigator</investigator_title>
  </responsible_party>
  <keyword>lymphoma</keyword>
  <keyword>body composition</keyword>
  <keyword>lean body mass</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>quality of life (QOL)</keyword>
  <keyword>nutritional status</keyword>
  <keyword>physical activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

